A draft guidance recommending the use of electroCore’s gammaCore device on the National Health Service (NHS) has been published by UK’s National Institute for Health and Care Excellence (NICE). The guidance covers use for cluster headaches.
GammaCore, a handheld non-invasive vagus nerve stimulator, aims to change pain signals for prevention and treatment of cluster headaches and migraines in adults.
The device is not compatible with all people with cluster headaches, so the guidance recommends that initially the patients should try it for three months before making the use permanent.
The clinical experts claimed that the treatment rate of this device in patients suffering from cluster headaches stands at 25%.
The NICE recommendation serves a great platform for this new device and NHS is already offering it free of charge to patients to help alleviate painful symptoms.
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like